Our Technology

The serpin (serine protease inhibitor) superfamily constitutes the largest protein class of serine/cysteine protease inhibitors, and regulate diverse biological processes. While considered to be ideal drug targets, therapeutic advances achieved through successful targeting of serpins have been challenging due to structural complexities of this protein class. Inhibitory serpins adopt a metastable conformation, and are structurally defined by multiple resting states and interactions with partner proteins. This functional flexibility, broad tissue distribution, multiple conformations and unique inhibitory mechanism of action ultimately provides an opportunity for identifying new drug targets. MDI Therapeutics has developed a proprietary expertise in serpin biology that has resulted in a structure-based drug design platform leading to the identification of novel drug candidates.serpin